MRUS Wutah bathi EPS kuartalan Merus

MRUS (Merus) - tandha merek perusahaan

Merus N.V. (MRUS) innovative Biclonics antibodies establish the foundation for tumor therapy, which determines the growth rate of quarterly net earnings per share. The current 13.80 indicator reflects the status of EPS dynamics. Business efficiency relies on a compact staff of top scientists, while production and testing are fully outsourced to external partners, rendering the company dependent on contractors.

Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan Merus (MRUS): kanggo periode 04.07.2022 - 10.01.2026

Rincian analitis perusahaan Merus N.V.

- nilai pasar lan prakiraan target analis:
Bagan rega Merus|MRUS - Target konsensus
- data kapitalisasi pasar:
Kapitalisasi pasar Merus Corp|MRUS - Total Nilai Perusahaan
- indikator nilai aset resik miturut neraca:
Aset Bersih saben Siji Saham Merus|MRUS - Kapitalisasi Akuntansi|Rasio Nilai Pasar marang Nilai Buku merus.nl|MRUS - Gunggung Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Merus N.V.|MRUS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Merus N.V.|MRUS - Kewajiban utang agregat|Utang marang nilai buku Merus Corp|MRUS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Merus|Indikator likuiditas cepet merus.nl
- rincian bathi lan kelipatan pasar:
MRUS - Bathi pungkasan|Bathi sing dikarepake Merus N.V.|MRUS - Pangali rega marang bathi|Prakiraan rega marang bathi Merus Corp|MRUS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Merus Corp|MRUS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Merus|MRUS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan merus.nl|MRUS - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Merus N.V.
Ringkesan analitik perusahaan:Merus, MRUS
Barang unggulan Merus N.V.

For Merus N.V., a developer of bispecific antibodies for cancer treatment, profit dynamics serve as a key indicator of innovation commercialization. This metric measures the percentage change in net earnings per share compared to the same period last year. By analyzing the quarterly EPS growth rate, an investor determines the pace of business scaling and resilience to market shocks. A decline in this figure signals a slowdown in drug development efficiency, while steady growth confirms the market potential of the company's unique platform.

Analisis pesaing

Immutep (IMMP) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan Anixa Biosciences|ATOS (Atossa) - Wutah bathi EPS kuartalan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan Context Tx CNTX|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Mersana Therapeutics (MRSN)|briacell.com - Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ESSA Pharma EPIX|QTI - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan